{"protocolSection":{"identificationModule":{"nctId":"NCT00789373","orgStudyIdInfo":{"id":"12560"},"secondaryIdInfos":[{"id":"H3E-EW-S124","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"CTRI/2009/091/000113","type":"REGISTRY","domain":"India"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer","officialTitle":"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung Cancer."},"statusModule":{"statusVerifiedDate":"2018-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-11"},"primaryCompletionDateStruct":{"date":"2010-06","type":"ACTUAL"},"completionDateStruct":{"date":"2017-11","type":"ACTUAL"},"studyFirstSubmitDate":"2008-11-10","studyFirstSubmitQcDate":"2008-11-10","studyFirstPostDateStruct":{"date":"2008-11-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-06-20","resultsFirstSubmitQcDate":"2011-06-20","resultsFirstPostDateStruct":{"date":"2011-07-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-11-20","lastUpdatePostDateStruct":{"date":"2018-12-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will compare progression-free survival in patients with advanced non-squamous non-small cell lung cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be randomized 2:1 to receive either maintenance pemetrexed or placebo."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":939,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"pemetrexed + cisplatin followed by pemetrexed","type":"EXPERIMENTAL","description":"pemetrexed plus cisplatin followed by pemetrexed plus best supportive care","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin","Other: Best Supportive Care"]},{"label":"pemetrexed + cisplatin followed by placebo","type":"PLACEBO_COMPARATOR","description":"pemetrexed plus cisplatin followed by placebo plus best supportive care","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin","Drug: Placebo","Other: Best Supportive Care"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"Induction therapy: 500 mg/m\\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles","armGroupLabels":["pemetrexed + cisplatin followed by pemetrexed","pemetrexed + cisplatin followed by placebo"],"otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Cisplatin","description":"Induction therapy: Cisplatin: 75 mg/m\\^2, IV, on Day 1 of each 21-day cycle for 4 cycles","armGroupLabels":["pemetrexed + cisplatin followed by pemetrexed","pemetrexed + cisplatin followed by placebo"]},{"type":"DRUG","name":"Placebo","description":"Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation","armGroupLabels":["pemetrexed + cisplatin followed by placebo"]},{"type":"DRUG","name":"Pemetrexed","description":"Maintenance therapy: 500 mg/m\\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.","armGroupLabels":["pemetrexed + cisplatin followed by pemetrexed"],"otherNames":["Alimta","LY231514"]},{"type":"OTHER","name":"Best Supportive Care","description":"Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).","armGroupLabels":["pemetrexed + cisplatin followed by pemetrexed","pemetrexed + cisplatin followed by placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Investigator-assessed Objective Progression-free Survival (PFS)","description":"Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.","timeFrame":"Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)"}],"secondaryOutcomes":[{"measure":"Independently-assessed Objective Progression-free Survival (PFS)","description":"To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.","timeFrame":"Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)"},{"measure":"Overall Survival (OS)","description":"OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.","timeFrame":"Date of randomization to the date of death from any cause up to 39.5 months"},{"measure":"Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score","description":"The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)"},{"measure":"Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)","description":"Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)"},{"measure":"Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)"},{"measure":"Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase","description":"A summary of non-serious AEs is located in the Reported Adverse Event Module.","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)"},{"measure":"Percentage of Participants With Serious Adverse Events During Maintenance Phase","description":"A summary of serious adverse events is located in the Reported Adverse Event Module.","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)"},{"measure":"Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off","description":"Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.","timeFrame":"Baseline to date of measured progressive disease (up to 19.3 months)"},{"measure":"Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm\\*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm\\*100.","timeFrame":"Date of randomization to date of measured PD (up to 19.3 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for the Induction Phase:\n\n* You must sign an informed consent document for clinical research.\n* You must have Stage IIIB or IV nonsquamous Non-Small Cell Lung Cancer.\n* You must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.\n* You are allowed to have had prior radiation therapy as long as it was not to more than 25% of the bone marrow and did not include the whole pelvis. Thoracic radiation must be completed more than 30 days before the study. You must be recovered from the toxic effects (except hair loss).\n* You must have at least 1 measurable tumor lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines or disease that can be evaluated by computed tomography (CT) Scan.\n* Your test results assessing the function of your blood forming tissue, kidneys, and liver must be satisfactory.\n* You must be 18 years of age or older.\n* Women must be sterile, postmenopausal or on contraception and men must be on contraception or sterile (e.g. post-vasectomy).\n\nExclusion Criteria for the Induction Phase:\n\n* You cannot have squamous cell and/or mixed small cell, non-small cell lung cancer\n* You cannot have received other investigational drugs within the last 30 days of entering the trial.\n* You cannot have previously completed or withdrawn from this study or any other study investigating pemetrexed.\n* You cannot have other serious on-going illnesses including active infections.\n* You cannot have a serious cardiac condition, such as a heart attack, angina, or heart disease within 6 months of entering the trial.\n* You cannot have had another form of cancer other than superficial basal cell and superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the last 5 years. Patients with a history of low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed less than 5 years ago.\n* You cannot have known central nervous system (CNS) metastases, other than treated, stable brain metastasis.\n* You cannot be receiving nor have received any prior systemic anticancer therapy for lung cancer (including chemotherapy given after surgery in early-stage treatment).\n* You cannot have clinically significant third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).\n* You cannot have received a recent (within 30 days) or are receiving a yellow fever vaccination.\n* You are unable to stop taking more than 1.3 grams of aspirin on a daily basis or other non-steroidal anti-inflammatory drugs (NSAIDs).\n* You are unable or unwilling to take folic acid, injections of vitamin B12, or corticosteroids.\n* You cannot be pregnant or breastfeeding.\n\nInclusion criteria at Randomization for the Maintenance Phase:\n\n* You must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.\n* You must have documented radiographic evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Tumor assessment must occur between Cycle 4 (Day 1) of induction therapy and the date of randomization. This response does not have to be confirmed in order for the patient to be randomized to the maintenance phase.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Adelaide","state":"South Australia","zip":"5000","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Frankston","state":"Victoria","zip":"3199","country":"Australia","geoPoint":{"lat":-38.14458,"lon":145.12291}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wendouree","state":"Victoria","zip":"3355","country":"Australia","geoPoint":{"lat":-37.53078,"lon":143.82838}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aalst","zip":"9300","country":"Belgium","geoPoint":{"lat":50.93604,"lon":4.0355}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Brussels","zip":"1200","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Genk","zip":"3600","country":"Belgium","geoPoint":{"lat":50.965,"lon":5.50082}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gilly","zip":"6060","country":"Belgium","geoPoint":{"lat":50.42449,"lon":4.4789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sint-Niklaas","zip":"9100","country":"Belgium","geoPoint":{"lat":51.16509,"lon":4.1437}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Espoo","zip":"02740","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Helsinki","zip":"00290","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tampere","zip":"33520","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Avignon","zip":"84082","country":"France","geoPoint":{"lat":43.94834,"lon":4.80892}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dijon","zip":"21034","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Le Mans","zip":"72037","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Montpellier","zip":"F-34295","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nantes","zip":"44202","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Paris","zip":"75015","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vandœuvre-lès-Nancy","zip":"54511","country":"France","geoPoint":{"lat":48.66115,"lon":6.17114}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Frankfurt","zip":"60596","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gerlingen","zip":"70839","country":"Germany","geoPoint":{"lat":48.79954,"lon":9.06316}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Großhansdorf","zip":"D-22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hamburg","zip":"D-20251","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ulm","zip":"89075","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Athens","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chania","zip":"73300","country":"Greece","geoPoint":{"lat":35.51124,"lon":24.02921}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Neo Faliro","zip":"18547","country":"Greece","geoPoint":{"lat":37.9464,"lon":23.66736}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pátrai","zip":"26500","country":"Greece","geoPoint":{"lat":38.2462,"lon":21.73508}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bangalore","zip":"560 078","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bhopal","zip":"462001","country":"India","geoPoint":{"lat":23.25469,"lon":77.40289}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madurai","zip":"625020","country":"India","geoPoint":{"lat":9.919,"lon":78.11953}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mumbai","zip":"400 012","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Patna","zip":"800 014","country":"India","geoPoint":{"lat":25.59408,"lon":85.13563}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Avellino","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aviano","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Genova","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lido di Camaiore","zip":"55043","country":"Italy","geoPoint":{"lat":43.90012,"lon":10.2269}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monza","zip":"20052","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pisa","zip":"56100","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Reggio Emilia","zip":"42100","country":"Italy","geoPoint":{"lat":44.69825,"lon":10.63125}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rome","zip":"00149","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Udine","zip":"33100","country":"Italy","geoPoint":{"lat":46.0693,"lon":13.23715}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ede","zip":"6716 RP","country":"Netherlands","geoPoint":{"lat":52.03333,"lon":5.65833}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Groningen","zip":"9728 NT","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Harderwijk","zip":"3844 DG","country":"Netherlands","geoPoint":{"lat":52.34167,"lon":5.62083}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Heerlen","zip":"6419 PC","country":"Netherlands","geoPoint":{"lat":50.88365,"lon":5.98154}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Coimbra","zip":"3040-853","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lisbon","zip":"1099-035","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vila Franca de Xira","zip":"4434-502","country":"Portugal","geoPoint":{"lat":38.95525,"lon":-8.98966}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bucharest","zip":"022328","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cluj-Napoca","zip":"3400","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oradea","zip":"3700","country":"Romania","geoPoint":{"lat":47.0458,"lon":21.91833}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Manresa","zip":"308243","country":"Spain","geoPoint":{"lat":41.72815,"lon":1.82399}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sabadell","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Valencia","zip":"46017","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bornova","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.47921,"lon":27.2399}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sihhiye","zip":"06100","country":"Turkey (Türkiye)"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Zeytinburnu","zip":"034760","country":"Turkey (Türkiye)","geoPoint":{"lat":40.99441,"lon":28.90417}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aberdeen","state":"Scotland","zip":"AB25 2ZN","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guildford","state":"Surrey","zip":"GU2 7XX","country":"United Kingdom","geoPoint":{"lat":51.23536,"lon":-0.57427}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Birmingham","state":"West Midlands","zip":"B15 2TH","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Newcastle","zip":"NE7 7DN","country":"United Kingdom","geoPoint":{"lat":54.21804,"lon":-5.88979}}]},"referencesModule":{"references":[{"pmid":"29424248","type":"DERIVED","citation":"Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Visseren-Grul CM, San Antonio B, John WJ, Zimmermann AH, Chouaki N, Paz-Ares L. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 2018 May;34(5):865-871. doi: 10.1080/03007995.2018.1439462. Epub 2018 Mar 27."},{"pmid":"25104617","type":"DERIVED","citation":"Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P, Corral J, San Antonio B, Chouaki N, John W, Zimmermann A, Visseren-Grul C, Gridelli C. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov;15(6):418-25. doi: 10.1016/j.cllc.2014.06.007. Epub 2014 Jun 21."},{"pmid":"24419418","type":"DERIVED","citation":"Reck M, Paz-Ares LG, de Marinis F, Molinier O, Sahoo TP, Laack E, John W, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2014 Feb;9(2):205-13. doi: 10.1097/JTO.0000000000000076."},{"pmid":"23835707","type":"DERIVED","citation":"Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8."},{"pmid":"23328269","type":"DERIVED","citation":"Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Clin Ther. 2013 Jan;35(1):54-65. doi: 10.1016/j.clinthera.2012.12.013."},{"pmid":"23059776","type":"DERIVED","citation":"Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012 Nov;7(11):1713-21. doi: 10.1097/JTO.0b013e318267cf84."},{"pmid":"22341744","type":"DERIVED","citation":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16."},{"pmid":"20211022","type":"DERIVED","citation":"Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer. 2010 Mar 8;10:85. doi: 10.1186/1471-2407-10-85."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Induction Pemetrexed + Cisplatin","description":"pemetrexed: 500 mg/m\\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles.\n\ncisplatin: 75 mg/m\\^2, IV, on Day 1 of each 21-day cycle for 4 cycles."},{"id":"FG001","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"Following Induction, received 500 mg/m\\^2 maintenance pemetrexed, IV, on Day 1 of each 21-day cycle plus Best Supportive Care until progressive disease (PD) or treatment discontinuation."},{"id":"FG002","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"Following Induction, received placebo (normal saline \\[0.9% sodium chloride\\]) administered IV on Day 1 of every 21-day cycle plus Best Supportive Care until PD or treatment discontinuation."}],"periods":[{"title":"Induction","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"939"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"1 patient received maintenance therapy post-induction but was never randomized.","numSubjects":"540"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"399"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death Due to study disease","reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death due to adverse event","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death due to toxicity","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death due to procedure","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Investigator decision","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol entry criteria not met","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"220"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Maintenance","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"359"},{"groupId":"FG002","numSubjects":"180"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"359"},{"groupId":"FG002","numSubjects":"180"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"Death due to study disease","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Death due to adverse event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Death due to toxicity","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Investigator Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Protocol entry criteria not met","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"253"},{"groupId":"FG002","numSubjects":"152"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"8"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Participants On-Going at Data Cut-Off","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Induction Pemetrexed + Cisplatin","description":"pemetrexed plus cisplatin"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"939"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.3","lowerLimit":"24.4","upperLimit":"83.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"362"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"577"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"59"}]}]},{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"Multiple","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"871"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Portugal","categories":[{"measurements":[{"groupId":"BG000","value":"38"}]}]},{"title":"Greece","categories":[{"measurements":[{"groupId":"BG000","value":"34"}]}]},{"title":"Finland","categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"65"}]}]},{"title":"Turkey","categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"71"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"175"}]}]},{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"54"}]}]},{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"106"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"34"}]}]},{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"53"}]}]},{"title":"Romania","categories":[{"measurements":[{"groupId":"BG000","value":"55"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}]},{"title":"Netherlands","categories":[{"measurements":[{"groupId":"BG000","value":"48"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"126"}]}]},{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]}]},{"title":"Smoking Status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Ever Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"757"}]}]},{"title":"Never Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"175"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Investigator-assessed Objective Progression-free Survival (PFS)","description":"Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.11","lowerLimit":"3.15","upperLimit":"4.57"},{"groupId":"OG001","value":"2.83","lowerLimit":"2.60","upperLimit":"3.12"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"900 patients were planned to be enrolled in order to randomize 558 pts to maintenance therapy. This trial was powered for the primary endpoint, PFS (90% power, assuming 238 events with 52% censoring and a PFS Hazard Ratio (HR)=0.65, alpha=0.05). This trial was also powered for a secondary endpoint, OS (93% power, assuming 390 events with 30% censoring and an OS HR=0.70). Alpha was controlled for both a preliminary analysis (alpha=0.0001) and final analysis of OS (alpha=0.0499).","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.00006","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"0.79"}]},{"type":"SECONDARY","title":"Independently-assessed Objective Progression-free Survival (PFS)","description":"To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.","populationDescription":"Randomized participants with reviewable scan--(316/359 \\[88%\\] Maintenance arm and 156/180 \\[87%\\] Placebo comparator arm. The majority of unread scans (12.4%) were due to participants not completing 1 cycle of treatment by the data cutoff date (30 June 2010).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"156"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.94","lowerLimit":"2.96","upperLimit":"4.24"},{"groupId":"OG001","value":"2.60","lowerLimit":"2.23","upperLimit":"2.92"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"0.81"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.","populationDescription":"All randomized participants. In the Pemetrexed maintenance arm 103 (28.7%) participants were censored and in the Placebo maintenance arm 39 (21.7%) participants were censored.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of randomization to the date of death from any cause up to 39.5 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed and cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.86","lowerLimit":"12.75","upperLimit":"16.03"},{"groupId":"OG001","value":"11.01","lowerLimit":"9.95","upperLimit":"12.52"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Type 1 (alpha) error was controlled for the analyses of both PFS and OS in order to maintain an overall two-sided alpha level of 0.05 using a statistical gatekeeping and alpha spending scheme. The unconditional statistical power of the final OS analysis was 93%.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0195","pValueComment":"The predefined alpha for the final analysis of OS is 0.0498 for the unadjusted log-rank test.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.64","ciUpperLimit":"0.96","estimateComment":"Unadjusted HR from Cox model with treatment as the only cofactor."}]},{"type":"SECONDARY","title":"Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score","description":"The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).","populationDescription":"Participants who were randomized and completed the EQ-5D at baseline and at least once post-baseline. For Cycle 17 and 18, there is no data available for the pemetrexed + cisplatin followed by placebo arm. No participants completed so zero participants were analyzed.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"153"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"153"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.21"},{"groupId":"OG001","value":"0.79","spread":"0.18"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.15"},{"groupId":"OG001","value":"-0.01","spread":"0.17"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.19"},{"groupId":"OG001","value":"0.01","spread":"0.17"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"83"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.15"},{"groupId":"OG001","value":"0.03","spread":"0.17"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.15"},{"groupId":"OG001","value":"0.02","spread":"0.18"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.16"},{"groupId":"OG001","value":"0.01","spread":"0.22"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.18"},{"groupId":"OG001","value":"0.04","spread":"0.14"}]}]},{"title":"Cycle 7 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.20"},{"groupId":"OG001","value":"0.01","spread":"0.13"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.18"},{"groupId":"OG001","value":"0.05","spread":"0.15"}]}]},{"title":"Cycle 9 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.20"},{"groupId":"OG001","value":"0.06","spread":"0.18"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.16"},{"groupId":"OG001","value":"0.08","spread":"0.15"}]}]},{"title":"Cycle 11 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.19"},{"groupId":"OG001","value":"0.04","spread":"0.17"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.27"},{"groupId":"OG001","value":"0.06","spread":"0.16"}]}]},{"title":"Cycle 13 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.27"},{"groupId":"OG001","value":"0.0","spread":"0.0"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.26"},{"groupId":"OG001","value":"0.03","spread":"0.05"}]}]},{"title":"Cycle 15 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.34"},{"groupId":"OG001","value":"0.01","spread":"0.02"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.36"},{"groupId":"OG001","value":"0.0","spread":"0.0"}]}]},{"title":"Cycle 17 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.43"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.52"}]}]},{"title":"30 Day Post-Study Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.27"},{"groupId":"OG001","value":"-0.09","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)","description":"Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).","populationDescription":"Participants who were randomized and completed the EQ-5D at baseline and at least once post-baseline. For Cycle 17 and 18, there is no data available for the pemetrexed + cisplatin followed by placebo arm. No participants completed so zero participants were analyzed.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"148"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":"16.6"},{"groupId":"OG001","value":"71.0","spread":"15.8"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"126"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":"9.86"},{"groupId":"OG001","value":"1.42","spread":"10.2"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"11.2"},{"groupId":"OG001","value":"3.15","spread":"13.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"10.9"},{"groupId":"OG001","value":"4.90","spread":"16.9"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"13.1"},{"groupId":"OG001","value":"6.15","spread":"16.4"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"12.4"},{"groupId":"OG001","value":"5.99","spread":"13.1"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"12.5"},{"groupId":"OG001","value":"5.76","spread":"12.9"}]}]},{"title":"Cycle 7 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"14.5"},{"groupId":"OG001","value":"3.98","spread":"10.9"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.12","spread":"14.1"},{"groupId":"OG001","value":"7.58","spread":"14.8"}]}]},{"title":"Cycle 9 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":"14.2"},{"groupId":"OG001","value":"7.61","spread":"16.7"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.14","spread":"15.1"},{"groupId":"OG001","value":"6.23","spread":"18.7"}]}]},{"title":"Cycle 11 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.58","spread":"14.7"},{"groupId":"OG001","value":"0.94","spread":"15.4"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"16.0"},{"groupId":"OG001","value":"4.63","spread":"13.1"}]}]},{"title":"Cycle 13 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.29","spread":"16.4"},{"groupId":"OG001","value":"10.0","spread":"3.27"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":"18.4"},{"groupId":"OG001","value":"14.0","spread":"4.55"}]}]},{"title":"Cycle 15 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.40","spread":"12.9"},{"groupId":"OG001","value":"12.0","spread":"3.46"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.83","spread":"9.99"},{"groupId":"OG001","value":"15.0","spread":"0.0"}]}]},{"title":"Cycle 17 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"21.1"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"14.1"}]}]},{"title":"30 days post-study","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.77","spread":"17.3"},{"groupId":"OG001","value":"-3.92","spread":"16.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}]}],"classes":[{"title":"Hospitalization due to Drug-related Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"8.4"},{"groupId":"OG001","value":"3.3"}]}]},{"title":"Transfusions Packed Red Blood Cells","categories":[{"measurements":[{"groupId":"OG000","value":"12.3"},{"groupId":"OG001","value":"4.4"}]}]},{"title":"Transfusions Whole Blood","categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Transfusions Platelets","categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"0.6"}]}]},{"title":"Transfusions Fresh Frozen Plasma","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase","description":"A summary of non-serious AEs is located in the Reported Adverse Event Module.","populationDescription":"Randomized population with 2% cut-off threshold for inclusion for 19.3 months and 5% for 49.7 months.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed Plus Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}]}],"classes":[{"title":"Non-Serious AEs at 2% Threshold: up to 19.3 Month","categories":[{"measurements":[{"groupId":"OG000","value":"59.9"},{"groupId":"OG001","value":"50.6"}]}]},{"title":"Non-Serious AEs at 5% Threshold: up to 49.7 Months","categories":[{"measurements":[{"groupId":"OG000","value":"75.5"},{"groupId":"OG001","value":"62.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serious Adverse Events During Maintenance Phase","description":"A summary of serious adverse events is located in the Reported Adverse Event Module.","populationDescription":"Randomized population with all serious adverse events included.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed Plus Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}]}],"classes":[{"title":"Serious Adverse Events: up to 19.3 Months","categories":[{"measurements":[{"groupId":"OG000","value":"18.9"},{"groupId":"OG001","value":"12.2"}]}]},{"title":"Serious Adverse Events: up to 49.7 Months","categories":[{"measurements":[{"groupId":"OG000","value":"26.2"},{"groupId":"OG001","value":"20.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off","description":"Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to date of measured progressive disease (up to 19.3 months)","groups":[{"id":"OG000","title":"Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed and best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2"},{"groupId":"OG001","value":"42.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm\\*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm\\*100.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Date of randomization to date of measured PD (up to 19.3 months)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care"},{"id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed + cisplatin followed by placebo plus best supportive care"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}]}],"classes":[{"title":"Response Rate","categories":[{"measurements":[{"groupId":"OG000","value":"46.2","lowerLimit":"41.0","upperLimit":"51.6"},{"groupId":"OG001","value":"42.2","lowerLimit":"34.9","upperLimit":"49.8"}]}]},{"title":"Disease Control Rate","categories":[{"measurements":[{"groupId":"OG000","value":"98.1","lowerLimit":"96.0","upperLimit":"99.2"},{"groupId":"OG001","value":"94.4","lowerLimit":"90.0","upperLimit":"97.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From start of study up to approximately 108 months","eventGroups":[{"id":"EG000","title":"Induction Pemetrexed + Cisplatin","description":"pemetrexed: 500 mg/m\\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles.\n\ncisplatin: 75 mg/m\\^2, IV, on Day 1 of each 21-day cycle for 4 cycles.","seriousNumAffected":257,"seriousNumAtRisk":939,"otherNumAffected":759,"otherNumAtRisk":939},{"id":"EG001","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed","description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","seriousNumAffected":94,"seriousNumAtRisk":359,"otherNumAffected":287,"otherNumAtRisk":359},{"id":"EG002","title":"Pemetrexed + Cisplatin Followed by Placebo","description":"pemetrexed and cisplatin followed by placebo plus best supportive care","seriousNumAffected":36,"seriousNumAtRisk":180,"otherNumAffected":117,"otherNumAtRisk":180}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":13,"numAtRisk":939},{"groupId":"EG001","numEvents":21,"numAffected":11,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":939},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":939},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":939},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Atrial tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Atrial thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Diastolic dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":180}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":14,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Diabetic retinopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":6,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Abdominal adhesions","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":24,"numAtRisk":939},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Neutropenic colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Retroperitoneal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":29,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":939},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":7,"numAtRisk":939},{"groupId":"EG001","numEvents":17,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":7,"numAtRisk":939},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":180}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":939},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":180}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Thrombosis in device","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":10,"numAffected":1,"numAtRisk":180}]},{"term":"Bile duct obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hepatomegaly","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":10,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Lung infection pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":17,"numAtRisk":939},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":359},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":180}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Rotavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Scrotal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":577},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":112}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":180}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Fracture displacement","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Splenic rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":6,"numAffected":1,"numAtRisk":180}]},{"term":"Tracheal obstruction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Transfusion reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Venous injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Biopsy pleura","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Blood creatinine decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hypercreatininaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":8,"numAffected":4,"numAtRisk":180}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":9,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":5,"numAffected":1,"numAtRisk":180}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":7,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Spinal disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Spondylitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Tumour necrosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cerebellar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":4,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":180}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":939},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Facial paresis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":19,"numAffected":5,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hemiplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":8,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":180}]},{"term":"Pyramidal tract syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Speech disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":180}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":362},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":158},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":362},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":158},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Bladder diverticulum","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":939},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Renal tubular necrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Testicular pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":577},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":112}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":4,"numAffected":1,"numAtRisk":180}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":15,"numAtRisk":939},{"groupId":"EG001","numEvents":12,"numAffected":6,"numAtRisk":359},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":180}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":180}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":11,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":180}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":180}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":28,"numAtRisk":939},{"groupId":"EG001","numEvents":14,"numAffected":3,"numAtRisk":359},{"groupId":"EG002","numEvents":7,"numAffected":3,"numAtRisk":180}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":180}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Catheter removal","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Arterial thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Arterial thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Iliac artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":11,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Ischaemic limb pain","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Jugular vein distension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":180}]},{"term":"Superior vena caval occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":939},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":939},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":359},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":180}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":600,"numAffected":152,"numAtRisk":939},{"groupId":"EG001","numEvents":295,"numAffected":76,"numAtRisk":359},{"groupId":"EG002","numEvents":11,"numAffected":5,"numAtRisk":180}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":340,"numAffected":158,"numAtRisk":939},{"groupId":"EG001","numEvents":100,"numAffected":38,"numAtRisk":359},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":180}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":339,"numAffected":131,"numAtRisk":939},{"groupId":"EG001","numEvents":110,"numAffected":23,"numAtRisk":359},{"groupId":"EG002","numEvents":47,"numAffected":14,"numAtRisk":180}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":175,"numAffected":114,"numAtRisk":939},{"groupId":"EG001","numEvents":44,"numAffected":28,"numAtRisk":359},{"groupId":"EG002","numEvents":16,"numAffected":7,"numAtRisk":180}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":932,"numAffected":362,"numAtRisk":939},{"groupId":"EG001","numEvents":286,"numAffected":69,"numAtRisk":359},{"groupId":"EG002","numEvents":15,"numAffected":8,"numAtRisk":180}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":366,"numAffected":210,"numAtRisk":939},{"groupId":"EG001","numEvents":78,"numAffected":42,"numAtRisk":359},{"groupId":"EG002","numEvents":14,"numAffected":9,"numAtRisk":180}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":494,"numAffected":141,"numAtRisk":939},{"groupId":"EG001","numEvents":325,"numAffected":51,"numAtRisk":359},{"groupId":"EG002","numEvents":16,"numAffected":8,"numAtRisk":180}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":139,"numAffected":44,"numAtRisk":939},{"groupId":"EG001","numEvents":77,"numAffected":18,"numAtRisk":359},{"groupId":"EG002","numEvents":13,"numAffected":6,"numAtRisk":180}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":743,"numAffected":181,"numAtRisk":939},{"groupId":"EG001","numEvents":316,"numAffected":55,"numAtRisk":359},{"groupId":"EG002","numEvents":61,"numAffected":16,"numAtRisk":180}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":50,"numAtRisk":939},{"groupId":"EG001","numEvents":50,"numAffected":21,"numAtRisk":359},{"groupId":"EG002","numEvents":9,"numAffected":5,"numAtRisk":180}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":168,"numAffected":42,"numAtRisk":939},{"groupId":"EG001","numEvents":314,"numAffected":45,"numAtRisk":359},{"groupId":"EG002","numEvents":18,"numAffected":5,"numAtRisk":180}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":46,"numAtRisk":939},{"groupId":"EG001","numEvents":65,"numAffected":38,"numAtRisk":359},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":180}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":316,"numAffected":119,"numAtRisk":939},{"groupId":"EG001","numEvents":91,"numAffected":32,"numAtRisk":359},{"groupId":"EG002","numEvents":21,"numAffected":6,"numAtRisk":180}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":127,"numAffected":31,"numAtRisk":939},{"groupId":"EG001","numEvents":155,"numAffected":23,"numAtRisk":359},{"groupId":"EG002","numEvents":15,"numAffected":7,"numAtRisk":180}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":30,"numAtRisk":939},{"groupId":"EG001","numEvents":55,"numAffected":18,"numAtRisk":359},{"groupId":"EG002","numEvents":14,"numAffected":3,"numAtRisk":180}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":17,"numAtRisk":939},{"groupId":"EG001","numEvents":118,"numAffected":17,"numAtRisk":359},{"groupId":"EG002","numEvents":36,"numAffected":13,"numAtRisk":180}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":250,"numAffected":67,"numAtRisk":939},{"groupId":"EG001","numEvents":79,"numAffected":29,"numAtRisk":359},{"groupId":"EG002","numEvents":26,"numAffected":11,"numAtRisk":180}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":235,"numAffected":73,"numAtRisk":939},{"groupId":"EG001","numEvents":201,"numAffected":43,"numAtRisk":359},{"groupId":"EG002","numEvents":54,"numAffected":17,"numAtRisk":180}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":48,"numAtRisk":939},{"groupId":"EG001","numEvents":65,"numAffected":15,"numAtRisk":359},{"groupId":"EG002","numEvents":13,"numAffected":9,"numAtRisk":180}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Canada"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"}]}},"hasResults":true}